Member Info for moonparty

RR, excellent question - I've had all immunisations so far, and contracted Omicron twice (and original once), so I see little , if any benefit in getting the booster currently on offer?
Would be interested to hear others opinions / take on the science here.
I predict low uptake of the Autumn booster...

"there is no need to speak when there is nothing to say" - I believe that is what they call irony :)

Sorry, couldn't resist. Have a good weekend all.

Bookies generally work in fixed outcome markets, which is a different model to share investment, and the mechanisms and maths involved are very different.

For markets it is generally supply and demand that determines price, which is subject to the whim of investors, in the case of AIM, mainly private investors. For larger stocks, it is professional investors and fund managers, which is where I think price becomes more aligned to 'true' value (whatever that may mean) because the processes involved are more objective and rational. But even here, market valuations are often considerably wrong.

For AIM stocks, all sorts of factors come in to play - sentiment, cost of living (investors have less to invest), expectations (realistic or not) of news. For illiquid stocks like Scancell, individual large shareholders can have a large effect if forced to sell (as evidenced by lochinvarlass recently), or conversely if building a large position.
Sadly, objectivity and research are probably towards the bottom of the list of factors.

Good discussion though, and both bookies and markets are valid price discovery mechanisms, each with their own quirks and limitations. An objective, hard working researcher can succeed in beating both!

Full disclosure - I have an MSc in Economics!

Kashdog, completely agree that bookies usually get it right, but can't agree that the 'market', which is not a bookie, always gets it right.
For a relatively known, dividend paying stock, perhaps, but for start-ups and AIM companies it rarely gets it right.
And that's where good research and patience (so much patience) comes in.

Forced sell by Lochinvarlass - disclosed on this BB if you check back a few days, at 11.721p, so the MM's are still working those shares. Shouldn't go any lower as they won't sell them at a loss (famous last words!)

LL, thanks for letting us know about your sells, it is good to know it was a 'friendly' sell and that there is no more to come. Good luck with the investment and hope you enjoy the weekend.

Not so sure if it was a sell - there was a large 715K delayed sell from 11.58, other large trades may actually be buys?
Anyways, we will probably never know the truth.
C7, current funds will cover all current trials, and I think it has been stated or at least intimated that deals are expected to be done, so hopefully, no further fund raises? Also, ' falling value attached to Covidity' - I agree the hot covid money has moved on to pastures new (and that accounts for some of the sp fall this year), but I don't think the value is falling currently - an update is due anytime, and the value of a universal covid vaccine (if it works) is immense.

Can't believe the sp is now lower than before the ModiFY safety announcement.
Cheeky top-up 80,321 shares at 12.45p
GLA

I would also add, that it is likely deals were discussed and rejected as LD and the team were not prepared to let the tech go for too small a sum. But this is just my opinion, can't verify it.

So, the initial excellent SCIB1 results didn't lead to a buyout / deal because of a perfect storm of factors:
- they had a buyer lined up, who pulled out late in the process (if I remember correctly because the guys at the top put the brakes on it even though the scientists were keen and due diligence was positive, though I think this info was released much later and informally).
- there had been failures in cancer vaccines in the industry and the pharma zeitgeist had gone cold on them
- it was only a phase 1 trial with limited numbers, and I believe other potential suitors required more comprehensive data. This combined with the change in industry opinion on cancer vaccines made it a more difficult sell.

Completely different situation to now, IMO. If moditope works, Scancell will have no problem attracting suitors in the current climate and with the current trail numbers.

It also highlights how little competition there is for covidity as a universal vaccine.
Please Scancell can we have an update!

(that would be multiple billions market cap!)

I've said this before - I (and many others) don't invest in early stage bio for a 2 or 3 bagger, we invest for a potential 10, 100, 1000 bagger. It's a big risk to invest as most fail, and this is where the research comes in.
For me, Scancell's risk is mitigated for from lab work results, previous human trial results and the endorsement within the scientific community of their work. Not to mention the substantial intellectual property they have 'land grabbed', and the fact (IMO) that Lindy is a scientific genius.

I'm hoping for an eventual price or takeout of multiple pounds, not unreasonable if they have success in their current trials, bearing in mind the size of the markets they are targeting.

Covidity is NOT a shot in the dark, it's based on an already proven platform (immunobody), and has already shown extremely promising results.

"So far, 22 people have been enrolled on the COVIDITY trial, and thus far the jabs have been well-tolerated, with no safety concerns.
In preclinical models, both have induced a significant immune response.
A data readout is expected in the second half of the year."
(from proactive 29 March update).

And that's just 1 of 4 ...

Nice try Kashdog, Scancell have not given away anything to ISA pharma - the amplivant is a required part of the final injectable drug. The drug is the prize, not the amplivant.
A bit like saying the fizzy water is worth 50% of coca-cola. Indeed, I think I did say this when someone tried to make this claim previously.

HRG,

As at 31st October (last published position), cash of £35.57 Million.
Cash burn was running at £5.4 million per 6 months, so if this continues, will still be sitting on just under £25 Million at 31st Oct 2022. Check last interims here:
https://www.lse.co.uk/rns/SCLP/interim-results-for-the-6-months-ended-31-oct-2021-c6and62h0bla1ue.html

So yes, plenty of money to see all current trials through. Enough to last for > 2 years at last reported cash burn rate.

"endlessly repeating the same stuff" oh the irony :)

AB, nobody here, to my recollection has said they are supporting Scancell in a purely altruistic way.
It's nice to know that the companies success will benefit people, but that's not the primary motive for investment at all.
All involved are sensible enough to know that without IP, investment in new drugs would cease and humanity would suffer. Read the article carefully - it's about adjusting IP to allow more widespread manufacture of the drugs.

rigga, because FPD happened over the weekend, and companies are obliged to RNS market sensitive information as soon as possible.

It really is fantastic news that all the years of dedication and painstaking work have finally reached the clinic.
It must be a proud day for Lindy and her team.

And, although the news was expected, it is still s major inflection point. I'm a little disappointed at the sp reaction, but it is a bloodbath out there today!